Form4insider filings, from the source

SEC Form 4 · accession 0001193805-15-001649

ANTARES PHARMA, INC. · ATRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
DEERFIELD PARTNERS, LP
10% Owner · Other
James E Flynn
10% Owner · Other
Period of report
Sep 28, 2015
Accepted (ET)
Sep 30, 2015 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Sep 28, 2015S288,726$1.8019D7,490,126IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Sep 28, 2015S226,857$1.8019D5,885,100IThrough Deerfield Partners, L.P.
Common StockF1,F2Sep 28, 2015S469,224$1.8147D7,020,902IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Sep 28, 2015S368,676$1.8147D5,516,424IThrough Deerfield Partners, L.P.
Common StockF1,F2Sep 29, 2015S42,728$1.81D6,978,174IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Sep 29, 2015S33,572$1.81D5,482,852IThrough Deerfield Partners, L.P.
Common StockF1,F2Sep 29, 2015S23,700$1.81D3,365,146IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Sep 29, 2015S19,976$1.8208D6,958,198IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Sep 29, 2015S15,696$1.8208D5,467,156IThrough Deerfield Partners, L.P.
Common StockF1,F2Sep 29, 2015S11,081$1.8208D3,354,065IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Sep 29, 2015S43,845$1.83D6,914,353IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Sep 29, 2015S34,450$1.83D5,432,706IThrough Deerfield Partners, L.P.
Common StockF1,F2Sep 30, 2015S59,248$1.6921D3,294,817IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Sep 30, 2015S106,820$1.6921D6,807,533IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Sep 30, 2015S83,930$1.6921D5,348,776IThrough Deerfield Partners, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Avalanche Biotechnologies, Inc. filed with the Securities and Exchange Commission on July 30, 2014 by Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.